We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Pair of Molecular Regulators Maintains Normal Eosinophil Levels

By LabMedica International staff writers
Posted on 18 Nov 2013
An international team of cell biologists have identified the mechanism that regulates production of eosinophils by the blood marrow, which may lead to development of drugs to control diseases caused by an excess of these cells.

Eosinophils are immune cells responsible for combating certain infections such as multicellular parasites. More...
Along with mast cells, they also control mechanisms associated with allergy and asthma. Eosinophils develop in the bone marrow under the control of the central eosinophil growth factor interleukin 5 (IL-5) before migrating into the blood. In normal individuals, eosinophils make up about 1%–6% of white blood cells, and are about 12–17 micrometers in size. Under normal conditions, eosinophils are found in the medulla and the junction between the cortex and medulla of the thymus and in the lower gastrointestinal tract, ovary, uterus, spleen, and lymph nodes but not in the lung, skin, or esophagus. The presence of eosinophils in these latter organs is associated with disease.

Investigators at Tel Aviv University (Israel) and Cincinnati Children's Hospital Medical Center (Ohio, USA) searched for the molecular signals that regulate eosinophil production.

They reported in the November 10, 2013, online edition of the journal Nature Immunology that IL-5 activity in eosinophils was regulated by the paired immunoglobulin-like receptors PIR-A and PIR-B. PIR-A countered the activity of IL-5 and triggered eosinophil apoptosis. However, in eosinophilia the activity of PIR-A was blocked by overexpression of PIR-B, and the eosinophils did not die.

Experiments using a model system of asthmatic mice that lacked PIR-B showed that these animals had little expansion of eosinophils in their blood and lungs and less asthmatic inflammation in their lungs than normal mice. The lack of PIR-B prevented eosinophils from reaching harmful levels.

"The fundamental knowledge we have gained may one day yield new therapies to treat devastating eosinophilic disorders," said senior author Dr. Ariel Munitz, senior lecturer in microbiology and clinical immunology at Tel Aviv University.

Researchers are now seeking drugs to either enhance the toxic effect of PIR-A on eosinophils or to weaken PIR-B activity in order to reduce its inhibitory effect on PIR-A.

Related Links:

Tel Aviv University
Cincinnati Children's Hospital Medical Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
HPV Test
Allplex HPV28 Detection
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical Abstract (Ziegler, AG., Rewers, M.J., Achenbach, P. et al. Diabetologia (2026). https://doi.org/10.1007/s00125-026-06841-z)

International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.